Kyverna Therapeutics, Inc. Common Stock (KYTX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Kyverna Therapeutics, Inc. Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 7.50 $ — 54% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -69.4%
- ROCE > 15% -66.0%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0% failed
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 19.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 250 m net cash passed
- Operating cash flow covers the profits of the last three years 29 m failed
- Return on capital at 15% or higher, or up versus two years ago -66.0% failed
- Insiders hold at least 10% or are net buyers 7.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 305.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.88 | -3.03 – -2.59 | 0 | 21.0% | 5 |
| 12/31/2027 | -2.95 | -3.82 – -2.15 | 18 | -2.7% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.67 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.62 | – | 2 | – | -1,852.20 | -37 | -38 |
| 2025: Q1 | -0.73 | – | 0 | – | – | -45 | -45 |
| 2025: Q2 | -0.69 | – | 0 | – | – | -32 | -32 |
| 2025: Q3 | -0.61 | – | 0 | – | – | -43 | -44 |
| 2025: Q4 | -0.62 | – | 0 | -100.00 | – | -34 | -34 |
| 2026: Q1 | -0.65 | – | 0 | – | – | -42 | -42 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2021 | 6 | -26 | -26 | -1.02 | -22 | -46 | 85 |
| 2022 | 7 | -29 | -29 | -1.12 | -36 | 47 | 67 |
| 2023 | 0 | -62 | -60 | -0.09 | -52 | 49 | 75 |
| 2024 | 0 | -143 | -127 | -3.33 | -114 | 267 | 305 |
| 2025 | 0 | -170 | -161 | -3.64 | -154 | 232 | 294 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Kyverna Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der Spätphase, konzentriert sich auf die Entwicklung von Zelltherapien für Patienten mit Autoimmunerkrankungen.
| Employees | 129 |
|---|---|
| Headquarters | EmeryVille, CA |
| Address | 5980 Horton Street, 94608 EmeryVille, United States |
| Phone | 510 925 2492 |
| Website | kyvernatx.com |
| IPO Date | 8. Feb 2024 |
| ISIN | US5019761049 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christi L. Shaw | Executive Chairperson | 1967 |
| Warner Biddle | CEO & Director | 1967 |
| Naji H. Gehchan M.B.A., M.D. | Chief Medical & Development Officer | 1982 |
| Marc Grasso M.D. | Strategic Advisor | 1973 |
| Gregory Martini | Chief Financial Officer | 1989 |
| Tom Van Blarcom Ph.D. | Senior VP & Head of Research | – |
| Mayo Pujols | Chief Technology Officer | 1970 |
| Jessica Serra | Head of Investor Relations | – |
| Ritesh Srivastava | Chief Legal & Compliance Officer | – |
| Cara Bauer Ph.D. | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.